Contact Us marketing@medicilon.com
ABOUT
Company Profile
Corporate Culture
Management Team
Company History
Message from the CEO
Honors and Awards
SERVICES
SERVICES
01 Drug Discovery
Chemistry Research Biology Research Early Pharmacokinetics
02 Pharmaceutical Research
Intermediates Active Pharmaceutical Ingredients Pharmaceutical preparation Analytical Method Development and Quality Control CMC Filings Analytical Testing Center
03 Preclinical Research
Pharmacology & Pharmacodynamics Drug Safety Evaluation DMPK Bioanalysis IND Filings
PLATFORM
PLATFORM
01 One-stop Integrated Services
Liposome Drug Development Drug Discovery Pharmaceutical Research Preclinical Research Botanical Drug Preclinical R&D
02 Innovative Drug R&D Services
Peptide Drug Conjugate (PDC) Antibody Nucleic Acid Drug Cellular Immunotherapies mRNA Vaccine PROTAC ADC
03 Key Technical Services for Drug R&D
Cytokine and Biomarker Detection Metabolite Identification (MetID) Drug Forming Research Flow Cytometry Technology SEND Format Conversion Flow Sorting NanoString nCounter Detection Routes of Drug Administration
04 Drug Efficacy Evaluation for Common Diseases
Rodent Cerebrovascular Disease Inflammatory and Immune Diseases IO Pharmacodynamic Model
05 High-end Preparations Technology Platform
Skin Topical Preparation Ophthalmic drug Inhalation drug
06 Targeted Drugs R&D Services
STAT3-targeted Drugs R&D Service KRAS-targeted Drugs R&D Service GLP-1 New Drug R&D Service
07 Safety Assessment Lab of Process Chemistry

08 Public Services
CAREERS
Talent Development
Campus Recruitment
Recruitment
NEWS
Medicilon Events
Featured Stories
Market Events
Videos
A.C.E.
INVESTORS
Stock Information
Investment Contact
CLIENT CENTER
Intellectual Property Protection
Clients Testimonials
Downloads
Partnerships
Medicilon Support
Newsletters
CN
×
中
Message
Contact Us
Close Button
Back To Top
Online Message×
Click switch
Close Button
Customer Center
Customer Center
Case Studies Clients Testimonials Downloads Partnerships Intellectual Property Protection Newsletters
HomeClient CenterMedicilon SupportIND 100
IND 100 Publications
Oct 31,2020
ABM Therapeutics presented Medicilon with a commemorative trophy of "our first candidate compound"
On October 31, 2020, ABM Therapeutics awarded the "Our First Candidate Compound" commemorative trophy to Dr. Li Zhigang, Vice President of Research and Development of Medicilon Chemistry Department, to thank Medicilon for its FTE form of cooperation, the pharmaceutical and chemical team helped it discover and advance the first drug candidate ABM-1310 to enter the clinical phase I in the United States.
See More
ABM Therapeutics presented Medicilon with a commemorative trophy of "our first candidate compound"
Jul 20,2020
Medicilon assisted Hangzhou DAC Biotech in approval of clinical study of ADC drug DAC-002
On July 20, 2020, DAC Biotech's new ADC drug development, TROP2-ADC—DAC-002 was approved of clinical study by NMPA. for the indication of solid malignant tumor. Medicilon completed preclinical pharmacokinetic and toxicological studies in this project, accelerating the development process. DAC-002 is an ADC anti-Trop2 monoclonal antibody conjugated by an intelligent ligand against Tubulysin B analogue.Read more
See More
Medicilon assisted Hangzhou DAC Biotech in approval of clinical study of ADC drug DAC-002
Jun 04,2020
Congratualtions to Bio-Thera on obtaining NMPA’s approval of clinical trials of BAT1308
Congratualtions to Medicilon's partner, Bio-Thera, on obtaining NMPA's approval of clinical trials of BAT1308. On May 27th, 2020, Bio-Thera Solutions, Ltd, annouced the approval of
See More
Congratualtions to Bio-Thera on obtaining NMPA’s approval of clinical trials of BAT1308
May 26,2020
Congratulations on the Successful Listing of Kintor Pharma
On May 22, 2020, Kintor Pharmaceutical Limited (stock code: 9939. HK) was officially listed on the Hong Kong Stock Exchange. We medicilon extend the congratulations and best wishes. Medicilon has joined hands with in multiple pharmaceutical development projects in recent years, including external preclinical pharmacokinetic studies and safety evaluation of the androgen receptor antagonist FrestatinRead more
See More
Congratulations on the Successful Listing of Kintor Pharma
Mar 15,2020
Medicilon assisted Zhejiang Bolaatu Medical Technology Co., Ltd on PA1010 tablets with implied permission for clinical trials
On March 10, 2020, PA1010 tablets, which are independently developed by Zhejiang Bolaatu Medical Technology Co., Ltd, obtained the implied license for NMPA clinical trials. This is the first new drug declared by Bolaatu.  PA1010 is a new class I drug for chronic hepatitis B (CHB). Zhejiang Bolaatu is a new drug research and developmentRead more
See More
Medicilon assisted Zhejiang Bolaatu Medical Technology Co., Ltd on PA1010 tablets with implied permission for clinical trials
Feb 26,2020
Guangzhou Magpie Pharmaceuticals was approved by NMPA to start the clinical trials of MN-08 with the help of Medicilon
Guangzhou Magpie Pharmaceuticals announced the clinical trials of MN-08, a treatment for Idiopathic Pulmonary Artery Hypertension (IPAH).  IPAH is a progressive disease that affects the precapillary pulmonary vasculature.  IPAH is a rare and fatal disease which has a high mortality rate. During the collaboration between Magpie Pharmaceuticals and Medicilon, Medicilon completed the research and developmentRead more
See More
Guangzhou Magpie Pharmaceuticals was approved by NMPA to start the clinical trials of MN-08 with the help of Medicilon
Dec 27,2019
Medicilon Assists Neupharma's RX108 to Enter Phase I Clinical Trials
​Recently, Suzhou Neupharma, an important partner of Shanghai Medicilon, announced that RX208 China phase I clinical research has completed the administration of the first patient in Shanghai Dongfang Hispital.
See More
Medicilon Assists Neupharma's RX108 to Enter Phase I Clinical Trials
Dec 19,2019
Medicilon assists Cgenetech to accelerate the development of new anti-diabetic drugs
On December 7, 2019, the 2019 annual meeting of the Biomedical Branch of the Shanghai European and American Alumni Association was held in Shanghai Pudong
See More
Medicilon assists Cgenetech to accelerate the development of new anti-diabetic drugs
Nov 08,2019
The Launch Meeting was Held by Medicilon and DAC Biotech of the Contract Research on ADC Preclinical Study
Chuansha, Shanghai, Nov. 8th, 2019 — Medicilon held the launch meeting with Hangzhou DAC Biotech Co., Ltd to initiate the preclinical study of the antibody-drug-conjugate (ADC) DXC005, including the pharmacology study, DMPK study and the safety evaluation. Medicilon has previously completed integrated preclinical research on ADC drugs cooperating with DAC Biotech and other companies.
See More
The Launch Meeting was Held by Medicilon and DAC Biotech of the Contract Research on ADC Preclinical Study
Oct 30,2019
Medicilon assists pharmaceutical companies to successfully pass the consistency evaluation
Recently, Medicilon's CMC preparations have developed another success. Amlodipine besylate tablets, a cardiovascular drug 289 base drug project developed for customers for lowering blood pressure, has been obtained by the National Medical Products Administration (NMPA). This is one of the consistency evaluation drugs approved by Medicilon and its customers. The project lasted for nearly 3Read more
See More
Medicilon assists pharmaceutical companies to successfully pass the consistency evaluation
Stock Code
688202

Global

Address: 20 Maguire Road, Suite 103, Lexington, MA 02421(America)

Tel: +1(781)535-1428(U.S.)

Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK

Tel: 0044 7790 816 954 (Europe)

Email: marketing@medicilon.com

  

Address: 5th Floor, 62, Banpodae-ro 4-gil, Seocho-gu, Seoul, 06719 South Korea

Tel: +82 70-8269-5849

China

Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)

Postcode: 201299

Tel: +86 (21) 5859-1500 (main line)

Fax: +86 (21) 5859-6369

Facebook icon
Twitter icon
Linkedin icon
Youtube icon
© 2023 Shanghai Medicilon Inc. All rights reserved All Rights Reserved Privacy Policy
Website Map
-->